76 results about "Chickenpox" patented technology

The present application provides an RNA encoding a varicella-zoster (VZV) glycoprotein E (gE) or a variant thereof, the RNA comprising a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the nucleotide sequence represented by any one of SEQ ID NO: 11-18. The eight mRNAs provided by the invention can translate in cells, the expression level of the generated VZV gE protein is high, and the mRNAs can induce a mouse to generate a high-titer gE specific IgG antibody in a manner of intramuscular injection into the body of the mouse through a preparation formed by encapsulating the lipidosome nanoparticles.

The present invention relates to the field of immunology and the field of molecular virology, in particular to the field of prevention and treatment of varicella-zoster viruses. Specifically, the present invention relates to a truncated varicella-zoster virus gE protein (or a variant thereof) capable of be soluble expression in an Escherichia coli expression system, and use thereof in preventing and / or treating varicella-zoster virus infections.

This disclosure provides compositions, pharmaceutical preparations, and methods relating to circular polyribonucleotides encoding the expression of Varicella-Zoster Virus immunogens.

Disclosed are an mRNA vaccine encoding a varicella zoster virus (VZV) protein, a preparation method therefor, and use thereof. The mRNA vaccine is characterized by encoding at least the varicella zoster virus (VZV) gE protein, gH protein, and gL protein.

A varicella-zoster virus (VZV) nanoparticle protein, and a preparation method therefor and a use thereof. The VZV protein comprises a partial or full sequence of an amino acid sequence of an extracellular region of a VZV gE glycoprotein, with W at position 200 mutation to C and L at position 245 mutation to C in the amino acid sequence of the extracellular region of the VZV gE glycoprotein. By means of the rational optimization design of the amino acid sequence of the VZV gE protein by means of protein genetic engineering, the VZV gE recombinant protein modified with amino acid mutations has increased stability and immunogenicity compared with the VZV gE protein. Moreover, by further designing the protein structure, the VZV gE protein is repeatedly displayed on the surface of ferritin nanoparticles with the desired epitopes exposed, thereby further enhancing immunogenicity.

The present disclosure provides immunogenic compositions comprising RSV and VZV antigens, as well as their use in the prevention and / or treatment of VZV and RSV infections.

The invention provides application of sclareol in preparation of a medicine for preventing and treating varicella-zoster virus infection. A series of biological experiments show that the sclareol can obviously relieve the cytopathic effect caused by VZV infection under the concentration without obvious cytotoxicity; the gene expression quantity of VZV characteristic genes including an immediate early gene ORF62, an early gene ORF21 and a late gene ORF68 and the expression of an early protein IE62 and a late protein gE can be remarkably inhibited, so that the effect of resisting VZV infection is achieved. The results show that sclareol has obvious prevention and treatment effects on VZV, has small toxic and side effects, is safe and effective, and has an application prospect in preparation of drugs for treating and / or preventing VZV.

Described are modified Varicella Zoster Virus glycoprotein E (VZV gE) proteins having improved stability and / or immunogenicity compared to a non-modified VZV gE. Also described are associated nucleic acids, immunogenic compositions, and methods of using such modified VZV gE proteins in the treatment or prevention of shingles.

The present disclosure provides methods of inducing an immune response against varicella zoster virus (VZV) in a human subject. The methods provided herein comprise administering to a human subject an immunogenic composition (e.g., a vaccine) comprising an RNA molecule formulated in a lipid nanoparticle. The disclosure also relates to the use of the immunogenic composition for the prevention or treatment of herpes zoster in a human subject.

The invention relates to the technical field of biology, in particular to a multivalent pneumococcal polysaccharide-protein conjugate immunogenic composition for preventing pneumococcal and varicella-zoster virus infection as well as a preparation method and application of the multivalent pneumococcal polysaccharide-protein conjugate immunogenic composition. The immunogenic composition of the present invention comprises: at least one pneumococcal polysaccharide-protein conjugate wherein the pneumococcal polysaccharide is linked to a carrier protein through a covalent bond; the carrier protein is varicella-zoster virus glycoprotein E, namely VZV gE recombinant protein, and the amino acid sequence of the VZV gE recombinant protein is shown as SEQ ID NO: 3 or SEQ ID NO: 4. The immunogenic composition containing the multivalent pneumococcal polysaccharide-protein conjugate, provided by the invention, shows a remarkable synergistic interaction effect, and realizes a'dual enhancement 'effect.

Provided are modified varicella-zoster virus (VZV) gE polypeptide, a circular RNA encoding the modified VZV gE polypeptide, a linear RNA encoding the modified VZV gE polypeptide and the use thereof for inducing an antigen specific immune response in a subject, or preventing or treating VZV infection.

Herpesviridae glycoprotein B (gB) polypeptides comprising a modified ectodomain is stabilized in the prefusion state, enabling development of inhibitors and vaccines directed against these viral pathogens. Modifications to DI, DII, and DV subdomains are important to stabilization of gB in the prefusion state, and additional modifications result in a further improved stabilization of gB in the prefusion state. The gB can be derived from an Epstein Barr Virus (EBV), a Human Cytomegalovirus (CMV), a Human Herpesvirus 6 (HHV6), a Herpes Simplex Virus 1 (HSV1), or a Varicella Zoster Virus (VZV). Polypeptides, nucleic acid constructs, compositions, and methods of using same to elicit an immune response are described.

The application discloses a kind of enveloped virus inactivation preparation based on medium-chain triglyceride and application thereof, the present application relates to the technical field of biological medicine external preparation, including active ingredient and auxiliary material: the active ingredient includes: high-purity medium-chain triglyceride (MCT), preferably octanoic acid (C8) and capric acid (C10) triglyceride mixture, purity ≥99%; The auxiliary material includes: food-grade antioxidant, for preventing oxidation of preparation, the content of food-grade antioxidant is 0.01-0.05%w / w, with medium-chain triglyceride as active ingredient, through the physical and chemical synergistic effect, enveloped virus is efficiently killed, for treating stubborn skin mucosa infection diseases (such as stubborn flat warts, herpes labialis, genital herpes, etc.) caused by human papillomavirus (HPV), herpes simplex virus (HSV-1 / HSV-2), varicella-zoster virus and other enveloped viruses.

Provided are a primer-probe combination for real-time quantitative PCR, a related kit, and a method for using primers to measure the titers of measles, mumps and varicella virus pathogens. The method is applicable to clinical and laboratory detection, is fast and convenient, and has high sensitivity.

A pharmaceutical composition comprising: i) a herpes gE protein, an active fragment of the protein, a variant of the protein, or a mixture of at least two of them; ii) an immunostimulatory composition comprising a saponin and a CpG oligodeoxynucleotide, or consisting of an adjuvant comprising a saponin and a CpG oligodeoxynucleotide. Use of the pharmaceutical composition in the preparation of a medicament for preventing and / or treating a varicella-zoster virus infection and / or a varicella-zoster virus mediated disease. The pharmaceutical composition achieves an unexpected technical effect and can mediate a stronger immune response.

The invention discloses an immunogenic composition containing gE nanoparticles as well as a preparation method and application thereof, and relates to the technical field of biomedicine, the immunogenic composition comprises self-assembled gE nanoparticles and an oil-in-water emulsion adjuvant, and a self-assembled gE nanoparticle antigen comprises gE, a connecting peptide SGS and a gI polypeptide sequence containing Th epitopes; the oil-in-water type emulsion adjuvant is prepared from squalene, Tween 80, DL-alpha-tocopherol and / or Span 85. The immunogenic composition provided by the invention can be applied to vaccines for preventing varicella and / or herpes zoster and / or postherpetic neuralgia, so that the aims of improving the immunogenicity of the gE antigen and reducing side effects of the vaccines are fulfilled.

The invention discloses a gE fusion protein containing a gH Th epitope and a preparation method and application thereof, and relates to the technical field of biomedicine, the fusion protein comprises a varicella-zoster virus (VZV) glycoprotein E extracellular domain (gE) and a Th epitope-containing VZV glycoprotein H extracellular domain (gH) polypeptide. The gE fusion protein can be applied to VZV vaccines, and solves the technical problems of weak immunogenicity of gE antigens and serious side reaction of vaccines in vaccines prepared in the prior art. Compared with the Xinanlietaine, the vaccine taking the gE fusion protein as the antigen has the advantages that the variety and dosage of immunopotentiators are less, the immunogenicity is better, and the clinical side reaction is lower; besides, the gE fusion protein vaccine not only can induce a gE specific CMI reaction, but also can induce a gH specific CMI reaction, so that the effectiveness of the vaccine is further improved. In short, the gE fusion protein has good clinical application potential.

Provided herein are compositions and methods useful for the detection of herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), and varicella zoster virus (VZV). In particular, provided herein are compositions, methods, systems, kits, reagents and reaction mixtures related thereto for nucleic acid amplification and detection procedures for detecting HSV-1, HSV-2, and VZV in a sample.

Various nucleoside phosphate and phosphonate analogues are provided for treatment of viral infections. Methods of preparing the analogues, pharmaceutical compositions containing the analogues, and methods of using the analogues as antiviral compounds, especially against adenoviruses, coronaviruses, and varicella zoster viruses, are also provided.

Provided is a varicella zoster vaccine. Specifically, the vaccine comprises an immune composition, and the immune composition comprises an antigen component and a particle protein component. The particle protein component comprises a nanoparticle protein, and the antigen component and the particle protein component covalently bind to each other by means of a binding peptide 1 and a binding peptide 2 to form an immunogenic complex. Provided is a preparation method for the varicella zoster vaccine.

The present disclosure belongs to the technical field of mRNA vaccines, and specifically relates to a herpes zoster mRNA vaccine, a preparation method therefor, and a use thereof. The herpes zoster mRNA vaccine provided by the present disclosure comprises an RNA encoding a varicella-zoster virus gE glycoprotein or a variant thereof. The vaccine can prevent herpes zoster infection and its complications.

Embodiments of the present disclosure generally relate to a new class of compositions that include VZV IE62 or a derivative thereof (e.g., a mutant) and lipid particles. Embodiments of the present disclosure also relate to uses of the compositions for treating, alleviating, or reducing the severity of, various diseases or medical conditions in a patient. For example, embodiments described herein may be utilized for treating, alleviating, or reducing the severity of various neuroinflammation and related pathologies and diseases such as psoriasis, rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, multiple sclerosis, neuromyelitis optica, or dementia, among others.

To provide herpes zoster mRNA vaccine, a preparation method therefor, and use thereof.SOLUTION: Provided is a herpes zoster mRNA vaccine, comprising an RNA encoding a varicella-zoster virus gE glycoprotein or a variant thereof, wherein the vaccine can prevent herpes zoster infection and its complications.SELECTED DRAWING: Figure 2

The present application relates to the field of immunological detection, and particularly relates to a reagent for detecting varicella-zoster virus infection and a preparation method thereof. The reagent comprises R1 reagent and R2 reagent; the R1 reagent is a working solution of streptavidin magnetic beads, and the preparation method comprises the following steps: firstly coupling activated carboxyl magnetic beads with streptavidin; dialyzing the magnetic beads obtained by the first coupling to remove streptavidin physically combined with the magnetic beads; secondly coupling the dialyzed magnetic beads with streptavidin; quenching the magnetic beads obtained by the second coupling, and then placing the magnetic beads in a working solution to obtain the working solution; the working solution contains fetal bovine serum, bovine serum albumin and lysine; the R2 reagent is a biotinylated VZV gE recombinant protein, and the VZV gE recombinant protein is a varicella-zoster virus gE glycoprotein extracellular domain fragment expressed by human embryonic kidney cells. The reagent has high sensitivity and specificity in the detection of varicella-zoster virus infection.

The present invention relates to the field of biomedicine and discloses a method for preparing a formaldehyde-crosslinked recombinant herpes zoster vaccine, comprising the following steps: S1. expressing varicella-zoster virus glycoprotein E in Chinese hamster ovary cells using DNA recombination technology; S2. diluting the herpes zoster recombinant protein with a low-temperature buffer to a concentration of less than 1.0 mg / ml; S3. mixing the formaldehyde solution with the low-temperature buffer to obtain a crosslinking solution with a formaldehyde concentration of 0.4% to 2%; S4. mixing the diluted herpes zoster recombinant protein solution with the crosslinking solution for a crosslinking reaction to ensure sufficient reaction between the protein and the formaldehyde crosslinker; S5. terminating the crosslinking reaction by exchanging the solution with PBS buffer. Through formaldehyde crosslinking technology, low-temperature mixing, and precise control of the crosslinking reaction, the invention improves the immunogenicity and stability of the vaccine, effectively enhancing the vaccine's effectiveness during long-term storage and transportation.

The invention discloses a fluorescent MIRA kit and method for detecting a monkey varicella virus, and relates to the technical field of biology.The kit comprises a primer probe combination, a buffer solution A, a buffer solution B, freeze-dried enzyme powder and a nucleic acid extraction.The primer probe combination is optimally designed and synthesized on the basis of a monkey varicella virus ORF21 gene conserved sequence; according to the present invention, the monkey varicella virus detection method is established and optimized, and the reaction system is further constructed, such that the optimal reaction condition and the optimal primer pair are determined, the monkey varicella virus detection method is established and optimized, and the constructed detection method has advantages of high sensitivity, good specificity, simple operation, fast detection speed, low cost, and wide application prospect. The kit has an important application value in detecting whether a sample contains the monkey varicella virus or not.

Provided herein is a herpes zoster vaccine composition comprising a messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding a varicella zoster virus (VZV) glycoprotein E (gE), which is soluble VZV gE or full-length VZV gE, and a composition for inducing an immune response against herpes zoster comprising the herpes zoster vaccine composition.

The invention discloses a gene for coding soluble VZV-gB-SpyTag protein and application of the gene, and belongs to the technical field of genetic engineering and immunology. The nucleotide sequence of the gene is as shown in SEQ ID NO. 8. The invention provides a gene for coding soluble VZV-gB-SpyTag as well as a recombinant plasmid and a recombinant microorganism thereof, soluble VZV-gB-SpyTag protein is prepared, Fe-gB nanoparticles are further constructed, the nanoparticles are uniform in size, good in dispersity and stable in structure, the cellular immune effect of the VZV-gB protein can be remarkably improved, and the VZV-gB-SpyTag protein can be used for preparing the soluble VZV-gB-SpyTag protein. The resistance of the body to varicella-zoster virus is enhanced. The invention provides technical support for prevention and treatment of varicella-zoster virus.

The invention belongs to the technical field of medicine and biology, and particularly relates to a vaccine for preventing and / or treating herpes zoster. The antigen for herpes zoster provided by the invention is obtained by connecting varicella zoster virus gE protein and human IgG1 Fc fragment in series. Furthermore, by combining with an adjuvant prepared from squalene, Tween 80 and poloxamer 188, the side reaction of the traditional common adjuvant can be further reduced on the premise of keeping the immunopotentiation effect of the antigen unchanged, so that the invention has higher application value.

The present application relates to the technical field of biological medicine, in particular to a preparation method of varicella attenuated live vaccine, a freeze-drying protective agent and application thereof, which comprises the steps of cell culture, virus infection, complex enzymatic dissociation, protective ultrasonic disruption, clarification and collection, etc. The complex enzymatic dissociation adopts EDTA and recombinant trypsin combination to loosen the cells at low temperature; the protective ultrasonic disruption adopts a buffer solution containing trehalose and recombinant human blood albumin to resuspend the cells and perform intermittent ultrasonic disruption. The present application further provides a freeze-drying protective agent which is composed of trehalose, sorbitol, L-arginine, L-histidine and polyvinylpyrrolidone. The virus harvesting efficiency of the method is high, and the virus activity loss is small; the freeze-drying protective agent has good safety and excellent stability.